Use of Serum Concentrations of Interleukin-18 and Monocyte Chemoattractant Protein-1 as Prognostic Indicators in Primary Immune-Mediated Hemolytic Anemia in Dogs

Journal of Veterinary Internal Medicine

Volumn 25, Issue 1, 2011, Pages 76-82

  Kjelgaard Hansen, M ^a   Goggs, R ^b   Wiinberg, B ^a   Chan, D L ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b ROYAL VETERINARY COLLEGE   (United Kingdom)

Author keywords

Cytokine; Keratinocyte chemoattractant; Macrophage; Mortality

Indexed keywords

INTERLEUKIN 18; MONOCYTE CHEMOTACTIC PROTEIN 1;

ANIMAL; ANIMAL DISEASE; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD; DOG; DOG DISEASE; PREDICTIVE VALUE; PROSPECTIVE STUDY; STATISTICAL MODEL;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANIMALS; CHEMOKINE CCL2; DOG DISEASES; DOGS; INTERLEUKIN-18; LOGISTIC MODELS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES;

CANIS FAMILIARIS;

EID: 78651228381     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2010.0642.x     Document Type: Article

References (40)

1. Reimer ME, Troy GC, Warnick LD. Immune-mediated hemolytic anemia: 70 cases (1988-1996). J Am Anim Hosp Assoc 1999;35:384-391.
2. Klag AR, Giger U, Shofer FS. Idiopathic immune-mediated hemolytic anemia in dogs: 42 cases.1986-1990. J Am Vet Med Assoc 1993;202:783-788.
3. Fagiolo E, Vigevani F, Pozzetto U. High cytokine serum levels in patients with autoimmune hemolytic anaemia. Immunol Invest 1994;23:449-456.
4. Fagiolo E. Immunological tolerance loss vs. erythrocyte self antigens and cytokine network disregulation in autoimmune hemolytic anaemia. Autoimmun Rev 2004;3:53-59.
5. Fagiolo E, Toriani-Terenzi C. Th1 and Th2 cytokine modulation by IL10/IL12 imbalance in autoimmune hemolytic anaemia. Autoimmunity 2002;35:39-44.
6. McCullough S. Immune-mediated hemolytic anemia: Understanding the nemesis. Vet Clin North Am Small Anim Pract 2003;33:1295-1315.
7. Duffy AL, Olea-Popelka FJ, Eucher J, et al. Serum concentrations of monocyte chemoattractant protein-1 in healthy and critically ill dogs. Vet Clin Pathol 2010;39:302-305.
8. Scott-Moncrieff JC, Treadwell NG, McCullough SM, et al. Hemostatic abnormalities in dogs with primary immune-mediated hemolytic anemia. J Am Anim Hosp Assoc 2001;37:220-227.
9. Carr AP, Panciera DL, Kidd L. Prognostic factors for mortality and thromboembolism in canine immune-mediated hemolytic anemia: A retrospective study of 72 dogs. J Vet Intern Med 2002;16:504-509.
10. Esmon CT. Interactions between the innate immune and blood coagulation systems. Trends Immunol 2004;25:536-542.
11. Ataga KI, Cappellini MD, Rachmilewitz EA. Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. Br J Haematol 2007;139:3-13.
12. Horne MK III, Cullinane AM, Merryman PK, Hoddeson EK. The effect of red blood cells on thrombin generation. Br J Haematol 2006;133:403-408.
13. Hoffman PC. Immune hemolytic anemia-selected topics. Hematol Am Soc Hematol Educ Program 2006;1:13-18.
14. Mitchell KD, Kruth SA, Wood RD, Jefferson B. Serum acute phase protein concentrations in dogs with autoimmune hemolytic anemia. J Vet Intern Med 2009;23:585-591.
15. Kjelgaard-Hansen M, Jensen AL, Kristensen AT. Evaluation of a commercially available human C-reactive protein (CRP) turbidometric immunoassay for determination of canine serum CRP concentration. Vet Clin Pathol 2003;32:81-87.
16. Piek CJ, Junius G, Dekker A, et al. Idiopathic immune-mediated hemolytic anemia: Treatment outcome and prognostic factors in 149 dogs. J Vet Intern Med 2008;22:366-373.
17. Ishihara M, Fujino Y, Setoguchi A, et al. Evaluation of prognostic factors and establishment of a prognostic scoring system for canine primary immune-mediated hemolytic anemia. J Vet Med Sci 2010;72:465-470.
18. Griebsch C, Arndt G, Kohn B. Evaluation of different prognostic markers in dogs with primary immune-mediated hemolytic anemia. Berl Munch Tierarztl Wochenschr 2010;123:160-168 (in German).
19. Hosmer DW, Lemeshaw S. Model-building strategies and methods for logistic regression. In: Hosmer DW, Lemeshaw S, eds. Applied Logistic Regression, 2nd ed. New York: John Wiley & Sons; 91-142, 2000.
20. Okano S, Yoshida M, Fukushima U, et al. Usefulness of systemic inflammatory response syndrome criteria as an index for prognosis judgement. Vet Rec 2002;150:245-246.
21. Griebsch C, Arndt G, Raila J, et al. C-reactive protein concentration in dogs with primary immune-mediated hemolytic anemia. Vet Clin Pathol 2009;38:421-425.
22. Hoyer KK, Dooms H, Barron L, Abbas AK. Interleukin-2 in the development and control of inflammatory disease. Immunol Rev 2008;226:19-28.
23. Fickenscher H, Hor S, Kupers H, et al. The interleukin-10 family of cytokines. Trends Immunol 2002;23:89-96.
24. Mosser DM, Zhang X. Interleukin-10: New perspectives on an old cytokine. Immunol Rev 2008;226:205-218.
25. Jia T, Serbina NV, Brandl K, et al. Additive roles for MCP-1 and MCP-3 in CCR2-mediated recruitment of inflammatory monocytes during Listeria monocytogenes infection. J Immunol 2008;180:6846-6853.
26. Serbina NV, Pamer EG. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol 2006;7:311-317.
27. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): An overview. J Interferon Cytokine Res 2009;29:313-326.
28. Frink M, Lu A, Thobe BM, et al. Monocyte chemoattractant protein-1 influences trauma-hemorrhage-induced distal organ damage via regulation of keratinocyte-derived chemokine production. Am J Physiol Regul Integr Comp Physiol 2007;292:R1110-R1116.
29. D'Acquisto F, Maione F, Pederzoli-Ribeil M. From IL-15 to IL-33: The never-ending list of new players in inflammation. Is it time to forget the humble aspirin and move ahead? Biochem Pharmacol 2010;79:525-534.
30. de Jager W, Bourcier K, Rijkers GT, et al. Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. BMC Immunol 2009;10:52.
31. Szczepaniak WS, Zhang Y, Hagerty S, et al. Sphingosine 1-phosphate rescues canine LPS-induced acute lung injury and alters systemic inflammatory cytokine production in vivo. Transl Res 2008;152:213-224.
32. Kunitomi A, Konaka Y, Yagita M, et al. Humanized anti-interleukin 6 receptor antibody induced long-term remission in a patient with life-threatening refractory autoimmune hemolytic anemia. Int J Hematol 2004;80:246-249.
33. Sachdeva N, Asthana D. Cytokine quantification: Technologies and applications. Front Biosci 2007;12:4682-4695.
34. Zhou X, Fragala MS, McElhaney JE, Kuchel GA. Conceptual and methodological issues relevant to cytokine and inflammatory marker measurements in clinical research. Curr Opin Clin Nutr Metab Care 2010;13:541-547.
35. Sinnott VB, Otto CM. Use of thromboelastography in dogs with immune-mediated hemolytic anemia: 39 cases (2000-2008). J Vet Emerg Crit Care 2009;19:484-488.
36. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood 1991;78:2791-2808.
37. Feldman B, Handagama P, Lubberink A. Splenectomy as adjunctive therapy for immune-mediated thrombocytopenia and hemolytic anemia in the dog. J Am Vet Med Assoc 1985;187:617-619.
38. Horgan JE, Roberts BK, Schermerhorn T. Splenectomy as an adjunctive treatment for dogs with immune-mediated hemolytic anemia: Ten cases (2003-2006). J Vet Emerg Crit Care 2009;19:254-261.
39. Mathes M, Jordan M, Dow S. Evaluation of liposomal clodronate in experimental spontaneous autoimmune hemolytic anemia in dogs. Exp Hematol 2006;34:1393-1402.
40. Lunn KF. Innovative therapies for immune-mediated hemolysis in dogs. Proceedings ACVIM Annual Forum, Montreal, June 2009.